Payment overview · 2025
General Payments
$3,674.81
170 reported records · 35 companies
Healthcare provider profile · identity verified
Howard A Lippes, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · WILLIAMSVILLE, NY · NPI 1750343141
Verified facts
What the public records show
CMS Open Payments records show Howard A Lippes, MD received $3,674.81 in general payments during 2025 across 170 reported records.
Amgen Inc. accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Crysvita, Jardiance, Mounjaro, Prolia, Synthroid, Teriparatide.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
KYOWA KIRIN, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CRYSVITA as an associated drug or biological on 6629 records involving 4054 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Crysvita by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Mirum Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Chenodal as an associated drug or biological on 290 records involving 254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Chenodal by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Ozempic by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $481.04 | 13.1% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $280.24 | 7.6% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $241.16 | 6.6% | 6 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $239.63 | 6.5% | 11 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $215.19 | 5.9% | 8 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $177.12 | 4.8% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $172.19 | 4.7% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $167.97 | 4.6% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $166.92 | 4.5% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.65 | 4.3% | 9 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $117.20 | 3.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $107.36 | 2.9% | 5 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $92.18 | 2.5% | 4 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $90.17 | 2.5% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $80.26 | 2.2% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.63 | 2.1% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $75.23 | 2.0% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $70.69 | 1.9% | 3 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $68.41 | 1.9% | 3 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $62.68 | 1.7% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.54 | 1.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.87 | 1.5% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $54.64 | 1.5% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $50.56 | 1.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.98 | 1.3% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $44.43 | 1.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$38.40 | 1.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.66 | 0.9% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $27.53 | 0.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.78 | 0.7% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.45 | 0.7% | 1 | 2025 |
| Mirum Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.62 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.70 | 0.5% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $15.68 | 0.4% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $14.05 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,663.52 | 169 |
| Education | $11.29 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $379.23 | 15 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $239.63 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $224.73 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $222.43 | 11 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $218.29 | 5 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $215.19 | 8 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $177.12 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $172.19 | 11 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $113.04 | 7 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $92.18 | 4 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $90.17 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $84.23 | 6 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $80.26 | 3 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $75.63 | 3 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $75.23 | 3 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $70.69 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $68.05 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $68.05 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $68.05 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.69 | 3 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $62.68 | 3 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $62.68 | 3 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $62.68 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $62.54 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.67 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $55.67 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.87 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $52.59 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.14 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $44.43 | 2 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $38.40 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.53 | 2 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| CHOLBAM Normalized: cholbam |
Drug | Mirum Pharmaceuticals, Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| CTEXLI Normalized: ctexli |
Drug | Mirum Pharmaceuticals, Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| Sogroya Normalized: sogroya |
Biological | Novo Nordisk Inc | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| GENOTROPIN Normalized: genotropin |
Drug | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| MYALEPT Normalized: myalept |
Drug | Chiesi USA, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $11.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CRYSVITA crysvita |
2025 | Crysvita | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 189 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 307 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 24 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 63 | exact normalized | Medicare Part D |
| TERIPARATIDE teriparatide |
2025 | Teriparatide | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 51 |
| KYOWA KIRIN, INC. Exact reporting entity; no affiliate inference |
2025 | CRYSVITA open payments reported associated product |
CMS Open Payments — General Payments 6629 supporting records · 4054 recipient NPIs · example record 1222071307 |
Crysvita · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
307 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Mirum Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | Chenodal open payments reported associated product |
CMS Open Payments — General Payments 290 supporting records · 254 recipient NPIs · example record 1241155725 |
Chenodal · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
360 | 90 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 360 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 343 | 103 |
| Mounjaro | Tirzepatide | 307 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 211 | 58 |
| Jardiance | Empagliflozin | 189 | 51 |
| Methimazole | Methimazole | 126 | 35 |
| Metformin Hcl Er | Metformin Hcl | 107 | 34 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 33 |
| Ezetimibe | Ezetimibe | 103 | 35 |
| Lisinopril | Lisinopril | 100 | 32 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 94 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 93 | 31 |
| Metformin Hcl | Metformin Hcl | 93 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 37 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 88 | 27 |
| Hydrocortisone | Hydrocortisone | 80 | 16 |
| Spironolactone | Spironolactone | 72 | 24 |
| Humalog | Insulin Lispro | 64 | 20 |
| Synthroid | Levothyroxine Sodium | 63 | 20 |
| Irbesartan | Irbesartan | 61 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 60 | 28 |
| Farxiga | Dapagliflozin Propanediol | 58 | 19 |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Invokana | Canagliflozin | 54 | 14 |
| Losartan Potassium | Losartan Potassium | 53 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 41 | 18 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 34 | 12 |
| Insulin Lispro | Insulin Lispro | 32 | suppressed |
| Cabergoline | Cabergoline | 31 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Minoxidil | Minoxidil | 29 | 15 |
| Novolog | Insulin Aspart | 28 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 24 | suppressed |
| Prolia | Denosumab | 24 | 13 |
| Desmopressin Acetate | Desmopressin Acetate | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Tymlos | Abaloparatide | 22 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 16 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Chenodal | Chenodiol | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Crysvita | Burosumab-Twza | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sandostatin Lar Depot | Octreotide Acetate,mi-Spheres | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,674.81 · 170 records | Amgen Inc. | ABRYSVO, AFREZZA, AIRSUPRA, CHOLBAM, COMIRNATY, CRENESSITY, CRYSVITA, CTEXLI, ETERNA, EVENITY, FREESTYLE LIBRE 3, Flector, GENOTROPIN, IMCIVREE, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, Licart, MINIMED 780G, MOUNJARO, MYALEPT, MYCAPSSA, NEFFY, OTEZLA, Omnipod, PREVNAR 20, PROLIA, QULIPTA, RECORLEV, REPATHA, SOMAVERT, STRENSIQ, SYNTHROID, Sogroya, TEPEZZA, TERIPARATIDE, TWIIST, The Cologuard Plus Collection Kit, Tirosint, UBRELVY, UNITHROID, Wegovy, Xhance, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Crysvita play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error